VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PTGX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PTGXProtagonist Therapeutics, Inc.
$124.67$8.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
PTGX logo

Protagonist Therapeutics, Inc.

PTGX
NASDAQ · Immunology Biotech
$124.67
At close - Nov 17, 4:00 PM EST - USD
Market Cap$8.02B
P/E26.1x
52W High$160.81
Volume447.25K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Milestone-Driven Revenue Masks Persistent Operating Cash Burn

PTGX's reported profitability in 2026Q3, with revenue of $274.4M and net income of $220.0M, appears to rest on episodic partnership milestone recognition rather than a recurring commercial ramp, since trailing quarterly revenue sat near $46.0M and operating cash flow was -$23.2M in that same period.

GrowthMixed
ProfitabilityWeak
ValuationExpensive
TechnicalsMixed
Explore valuation models
MARKET ACTION

PTGX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

-24% Peers

P/E is 24% below peer median

03

Market leadership

RS 82 · Leader

High momentum (Outperforming 82% of market)

04

Mixed Trend

Mixed

Price < 50DMA but > 200DMA

Next CatalystEstimated earnings · Feb 5
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue swung from $4.7M in 2024Q3 to $274.4M in 2026Q3 and gross margins near 100% reflect license accounting rather than a demonstrated pricing advantage, while operating income remains dependent on lumpy milestone timing.

Analyst Consensus+42.2% target
Buy(26 analysts)
26 Buy0 Hold0 Sell

The Bull Case

Upside Catalysts

Proprietary peptide platform

PTGX's proprietary peptide engineering platform has already demonstrated innovation and execution potential in biotech.

Underappreciated clinical assets

The company's clinical assets are seen as undervalued, offering significant upside potential.

Strategic optionality

PTGX's strategic optionality, including partnerships or licensing opportunities, adds to its bullish case.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
PTGX+43.00%
S&P 500 (^GSPC)+7.21%
1-Year Return
PTGX+47.07%
S&P 500 (^GSPC)+10.03%
3-Year Return
PTGX+641.64%
S&P 500 (^GSPC)+51.03%
5-Year Return
PTGX+242.31%
S&P 500 (^GSPC)+57.68%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
26.1x
Forward P/E
26.6x
EV/EBITDA100th %ile
23.8x
FCF YieldCash Flow
1.4%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
26.1x
9.1x
100th· High
EV/EBITDA
23.8x
9.5x
100th· High
Price/FCF
72.4x
99.0x
50th· Fair
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$25.50-79.5%
Base (Fair)$48.09-63.3%
Bull$55.35-55.6%
$25.50 Bear$48.09 Base$55.35 Bull
Current Market Price: $124.67
Trades at a 159.2% premium to Base DCF ($48.09)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$46M-89.4% YoY
Net income FY25
-$130M-147.3% YoY
Free cash flow FY25
$56M-69.3% YoY
Operating margin FY25
-343.6%-401.8 pts YoY
ROIC (FY25)-21.8%
Avg ROIC 5Y-30.7%
ROE (TTM)42.8%
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
$3.07+0.3%
vs $3.06
$274M+10.0%
vs $249M
Q3 2026
Aug 5, 2026
$2.29+2.7%
vs $2.23
$213M+7.5%
vs $199M
Q2 2026
May 5, 2026
$0.05+107.7%
vs -$0.65
$56M+381.7%
vs $12M
Q1 2026
Feb 25, 2026
-$0.69-30.2%
vs -$0.53
$7M-14.9%
vs $9M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Zacks Investment Research·1d ago
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 37.6%

The average of price targets set by Wall Street analysts indicates a potential upside of 37.6% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research·Nov 5, 2026
Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass Estimates

Protagonist Therapeutics (PTGX) came out with quarterly earnings of $3.07 per share, beating the Zacks Consensus Estimate of $2.58 per share. This compares to a loss of $0.62 per share a year ago.

Zacks Investment Research·Oct 29, 2026
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research·Oct 29, 2026
Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Filtered for Protagonist Therapeutics, Inc.More Headlines
04

Compare before deciding

Benchmark PTGX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Protagonist Therapeutics, Inc. (PTGX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
PTGX logoPTGXProtagonist Therapeutics, Inc.Current
$124.67$8.02B26.13-89.41%62.04%42.83%—
IMVT logoIMVTImmunovant, Inc.
$33.21$6.85B-13.49—-7173.52%-63.01%—
KYMR logoKYMRKymera Therapeutics, Inc.
$121.52$10B-34.81-16.72%-341.87%-22.39%—
PRTA logoPRTAProthena Corporation plc
$8.26$432.44M-17.79-92.84%-45.43%-8.34%—
ACRS logoACRSAclaris Therapeutics, Inc.
$3.38$472.06M-6.34-58.19%-1244.09%-59.2%—
ARDX logoARDXArdelyx, Inc.
$3.18$785.55M-14.3322.09%-11.85%-35.3%—

Compare PTGX vs Peers

Protagonist Therapeutics, Inc. (PTGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IMVT

Most directly comparable listed peer for PTGX.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare PTGX against a more recognizable public peer.

Peer Set

Compare Top 5

vs IMVT, KYMR, PRTA, ACRS

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

PTGX SEC Filings & Documents

Protagonist Therapeutics, Inc. (PTGX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 5, 2026·SEC

Material company update

Aug 5, 2026·SEC

Material company update

Jun 18, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 25, 2026·SEC

FY 2025

Feb 21, 2025·SEC

FY 2024

Feb 27, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 6, 2026·SEC

FY 2026

Aug 5, 2026·SEC

FY 2026

May 5, 2026·SEC

Get notified when PTGX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PTGX Frequently Asked Questions

Protagonist Therapeutics, Inc. (PTGX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Protagonist Therapeutics, Inc.'s revenue?

Protagonist Therapeutics, Inc. (PTGX) reported $551.7M in revenue over the trailing twelve months. Revenue was $46.0M in fiscal year 2025.

How fast is Protagonist Therapeutics, Inc. growing?

Protagonist Therapeutics, Inc. (PTGX) grew revenue by 163.7% over the trailing twelve months, compared with the twelve months before.

Is PTGX profitable?

Yes. Protagonist Therapeutics, Inc. (PTGX) earned $342.3M in net income over the trailing twelve months (a 62.0% net margin).

Dividend & Returns
What is PTGX's return on equity?

Protagonist Therapeutics, Inc. (PTGX) had a return on equity (ROE) of 42.8% over the trailing twelve months. That is well above the market's typical 10-15%.

What is Protagonist Therapeutics, Inc.'s free cash flow?

Protagonist Therapeutics, Inc. (PTGX) generated $110.7M in free cash flow over the trailing twelve months.

What if you invested $1,000 in PTGX back in 2014?

Total return calculator · dividends reinvested · 12+ years of data

See returns →